-
Synageva BioPharma Q1 Net Loss Widens To $14.5 Mln From $7.4 Mln Last Year
5/7/2013
|
-
Synageva BioPharma Q4 Loss Per Share $0.62 Vs Loss $0.65 Last Year
3/11/2013
|
|
|
|
|
|
|
-
Synageva Says Begins Dosing In Phase 3 Trial Of Sebelipase Alfa In Children And Adults With Late Onset LAL Deficiency
2/11/2013
|
-
Hepatology Publishes 12-Week Phase I/II Extension Study Data Of Sebelipase Alfa In Adults With Late Onset LAL Deficiency
2/4/2013
|
|
|
|
|
|
|